Brokerages Set ICON Public Limited (NASDAQ:ICLR) Price Target at $279.17

ICON Public Limited (NASDAQ:ICLR) has been assigned a consensus recommendation of “Moderate Buy” from the fifteen research firms that are covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $279.17.

Several equities research analysts recently commented on ICLR shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $263.00 price target on shares of ICON Public in a report on Wednesday, January 15th. Barclays cut their price target on ICON Public from $275.00 to $240.00 and set an “overweight” rating for the company in a report on Friday, February 21st. Truist Financial cut their price target on ICON Public from $284.00 to $262.00 and set a “buy” rating for the company in a report on Thursday, February 13th. William Blair reaffirmed an “outperform” rating on shares of ICON Public in a report on Tuesday, January 14th. Finally, Robert W. Baird cut their target price on ICON Public from $221.00 to $203.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th.

Institutional Investors Weigh In On ICON Public

A number of institutional investors have recently modified their holdings of ICLR. First Horizon Advisors Inc. grew its stake in shares of ICON Public by 33.9% in the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after buying an additional 151 shares in the last quarter. Icon Wealth Advisors LLC grew its stake in ICON Public by 861.1% during the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after purchasing an additional 11,840 shares in the last quarter. Foyston Gordon & Payne Inc acquired a new position in ICON Public during the 3rd quarter worth $11,672,000. GAMMA Investing LLC grew its stake in ICON Public by 64.0% during the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after purchasing an additional 169 shares in the last quarter. Finally, Steph & Co. grew its stake in ICON Public by 3.7% during the 4th quarter. Steph & Co. now owns 1,560 shares of the medical research company’s stock worth $327,000 after purchasing an additional 55 shares in the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

ICON Public Price Performance

Shares of ICON Public stock opened at $183.96 on Tuesday. The business has a 50 day simple moving average of $193.43 and a two-hundred day simple moving average of $227.86. ICON Public has a 12 month low of $174.93 and a 12 month high of $347.72. The stock has a market capitalization of $14.86 billion, a P/E ratio of 19.30, a PEG ratio of 1.86 and a beta of 1.21. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.26 and a quick ratio of 1.34.

ICON Public (NASDAQ:ICLR) last announced its earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.01. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. The business had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $2.04 billion. As a group, analysts predict that ICON Public will post 13.38 EPS for the current fiscal year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.